ID   EDF1_HUMAN              Reviewed;         148 AA.
AC   O60869; Q5T5T2; Q9UIM1;
DT   12-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   18-JUN-2025, entry version 201.
DE   RecName: Full=Endothelial differentiation-related factor 1;
DE            Short=EDF-1;
DE   AltName: Full=Multiprotein-bridging factor 1;
DE            Short=MBF1;
GN   Name=EDF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, DEVELOPMENTAL
RP   STAGE, INDUCTION, AND FUNCTION.
RX   PubMed=9813014; DOI=10.1074/jbc.273.47.31119;
RA   Dragoni I., Mariotti M., Consalez G.G., Soria M.R., Maier J.A.M.;
RT   "EDF-1, a novel gene product down-regulated in human endothelial cell
RT   differentiation.";
RL   J. Biol. Chem. 273:31119-31124(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY,
RP   INTERACTION WITH TBP; NR5A1; FOS; JUN AND ATF1, SUBCELLULAR LOCATION, AND
RP   FUNCTION.
RX   PubMed=10567391; DOI=10.1074/jbc.274.48.34196;
RA   Kabe Y., Goto M., Shima D., Imai T., Wada T., Morohashi K., Shirakawa M.,
RA   Hirose S., Handa H.;
RT   "The role of human MBF1 as a transcriptional coactivator.";
RL   J. Biol. Chem. 274:34196-34202(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 2-13 AND 99-113, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [8]
RP   INTERACTION WITH CALM AND TBP, MUTAGENESIS OF THR-40; THR-58; THR-91 AND
RP   SER-111, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=10816571; DOI=10.1074/jbc.m001928200;
RA   Mariotti M., De Benedictis L., Avon E., Maier J.A.M.;
RT   "Interaction between endothelial differentiation-related factor-1 and
RT   calmodulin in vitro and in vivo.";
RL   J. Biol. Chem. 275:24047-24051(2000).
RN   [9]
RP   INTERACTION WITH NR5A2; NR1H3; PPARG AND TFIID COMPLEX, TISSUE SPECIFICITY,
RP   AND FUNCTION.
RX   PubMed=12040021; DOI=10.1210/mend.16.6.0843;
RA   Brendel C., Gelman L., Auwerx J.;
RT   "Multiprotein bridging factor-1 (MBF-1) is a cofactor for nuclear receptors
RT   that regulate lipid metabolism.";
RL   Mol. Endocrinol. 16:1367-1377(2002).
RN   [10]
RP   MUTAGENESIS OF THR-65; THR-74 AND SER-87, INTERACTION WITH TBP AND CALM,
RP   PHOSPHORYLATION, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=15112053; DOI=10.1007/s00018-004-4016-0;
RA   Ballabio E., Mariotti M., De Benedictis L., Maier J.A.M.;
RT   "The dual role of endothelial differentiation-related factor-1 in the
RT   cytosol and nucleus: modulation by protein kinase A.";
RL   Cell. Mol. Life Sci. 61:1069-1074(2004).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-4, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT LYS-25, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   STRUCTURE BY NMR OF 71-148.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the HTH domain of human EDF-1 protein.";
RL   Submitted (NOV-2005) to the PDB data bank.
CC   -!- FUNCTION: Transcriptional coactivator stimulating NR5A1 and ligand-
CC       dependent NR1H3/LXRA and PPARG transcriptional activities. Enhances the
CC       DNA-binding activity of ATF1, ATF2, CREB1 and NR5A1. Regulates nitric
CC       oxid synthase activity probably by sequestering calmodulin in the
CC       cytoplasm. May function in endothelial cells differentiation, hormone-
CC       induced cardiomyocytes hypertrophy and lipid metabolism.
CC       {ECO:0000269|PubMed:10567391, ECO:0000269|PubMed:12040021,
CC       ECO:0000269|PubMed:15112053, ECO:0000269|PubMed:9813014}.
CC   -!- SUBUNIT: Interacts with TBP and the transcription factor IID (TFIID)
CC       complex, NR5A2, NR1H3 and PPARG. Interaction with TBP is regulated by
CC       phosphorylation. Binds NR5A1, ATF1, FOS and JUN via their conserved
CC       basic region. Binding to calmodulin is regulated by calcium and
CC       phosphorylation of the IQ motif. {ECO:0000269|PubMed:10567391,
CC       ECO:0000269|PubMed:10816571, ECO:0000269|PubMed:12040021,
CC       ECO:0000269|PubMed:15112053}.
CC   -!- INTERACTION:
CC       O60869; P13569: CFTR; NbExp=3; IntAct=EBI-781301, EBI-349854;
CC       O60869; P03372: ESR1; NbExp=3; IntAct=EBI-781301, EBI-78473;
CC       O60869; P42858: HTT; NbExp=6; IntAct=EBI-781301, EBI-466029;
CC       O60869; P50222: MEOX2; NbExp=3; IntAct=EBI-781301, EBI-748397;
CC       O60869; Q13133: NR1H3; NbExp=4; IntAct=EBI-781301, EBI-781356;
CC       O60869; O00482: NR5A2; NbExp=2; IntAct=EBI-781301, EBI-781320;
CC       O60869; P37231: PPARG; NbExp=4; IntAct=EBI-781301, EBI-781384;
CC       O60869; P03495: NS; Xeno; NbExp=2; IntAct=EBI-781301, EBI-2548993;
CC       O60869-1; P20226: TBP; NbExp=2; IntAct=EBI-781310, EBI-355371;
CC       O60869-1; Q04752: NR5A1; Xeno; NbExp=4; IntAct=EBI-781310, EBI-850837;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Also nuclear upon
CC       binding to NR5A1 and treatment of cells with TPA or forskolin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=O60869-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta;
CC         IsoId=O60869-2; Sequence=VSP_013336;
CC       Name=3;
CC         IsoId=O60869-3; Sequence=VSP_054701;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, liver, lung, kidney and heart
CC       (at protein level). Ubiquitously expressed. More abundant in heart,
CC       pancreas, liver, intestine and adipose tissues.
CC       {ECO:0000269|PubMed:10567391, ECO:0000269|PubMed:12040021,
CC       ECO:0000269|PubMed:9813014}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in fetal tissues. More abundant in
CC       kidney. {ECO:0000269|PubMed:9813014}.
CC   -!- INDUCTION: Down-regulated by HIV-1 Tat or phorbol ester (TPA) treatment
CC       in endothelial cells (at mRNA and protein levels).
CC       {ECO:0000269|PubMed:9813014}.
CC   -!- DOMAIN: The IQ motif, which is involved in calmodulin binding, overlaps
CC       with the binding domain for nuclear receptors and transcription
CC       factors. Its phosphorylation probably allows a switch between the two
CC       activities of the protein (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated (by PKA and PKC). {ECO:0000269|PubMed:10816571,
CC       ECO:0000269|PubMed:15112053}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ005259; CAA06446.1; -; mRNA.
DR   EMBL; AB002282; BAA88073.1; -; mRNA.
DR   EMBL; AB002283; BAA88074.1; -; mRNA.
DR   EMBL; CR541914; CAG46712.1; -; mRNA.
DR   EMBL; BT009863; AAP88865.1; -; mRNA.
DR   EMBL; AL355987; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015500; AAH15500.1; -; mRNA.
DR   CCDS; CCDS65193.1; -. [O60869-3]
DR   CCDS; CCDS7011.1; -. [O60869-1]
DR   CCDS; CCDS7012.1; -. [O60869-2]
DR   RefSeq; NP_001268226.1; NM_001281297.2. [O60869-3]
DR   RefSeq; NP_001268227.1; NM_001281298.1.
DR   RefSeq; NP_001268228.1; NM_001281299.1.
DR   RefSeq; NP_003783.1; NM_003792.4. [O60869-1]
DR   RefSeq; NP_694880.1; NM_153200.3. [O60869-2]
DR   PDB; 1X57; NMR; -; A=71-148.
DR   PDB; 6ZVH; EM; 2.90 A; i=24-133.
DR   PDBsum; 1X57; -.
DR   PDBsum; 6ZVH; -.
DR   AlphaFoldDB; O60869; -.
DR   BMRB; O60869; -.
DR   EMDB; EMD-11456; -.
DR   SMR; O60869; -.
DR   BioGRID; 114260; 92.
DR   FunCoup; O60869; 2885.
DR   IntAct; O60869; 50.
DR   MINT; O60869; -.
DR   STRING; 9606.ENSP00000224073; -.
DR   ChEMBL; CHEMBL4295670; -.
DR   GlyGen; O60869; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; O60869; -.
DR   PhosphoSitePlus; O60869; -.
DR   BioMuta; EDF1; -.
DR   jPOST; O60869; -.
DR   MassIVE; O60869; -.
DR   PaxDb; 9606-ENSP00000224073; -.
DR   PeptideAtlas; O60869; -.
DR   ProteomicsDB; 49636; -. [O60869-1]
DR   ProteomicsDB; 49637; -. [O60869-2]
DR   Pumba; O60869; -.
DR   TopDownProteomics; O60869-1; -. [O60869-1]
DR   Antibodypedia; 18815; 222 antibodies from 32 providers.
DR   DNASU; 8721; -.
DR   Ensembl; ENST00000224073.6; ENSP00000224073.1; ENSG00000107223.13. [O60869-1]
DR   Ensembl; ENST00000371648.4; ENSP00000360711.4; ENSG00000107223.13. [O60869-2]
DR   Ensembl; ENST00000371649.5; ENSP00000360712.1; ENSG00000107223.13. [O60869-3]
DR   GeneID; 8721; -.
DR   KEGG; hsa:8721; -.
DR   MANE-Select; ENST00000224073.6; ENSP00000224073.1; NM_003792.4; NP_003783.1.
DR   UCSC; uc004cjt.3; human. [O60869-1]
DR   AGR; HGNC:3164; -.
DR   CTD; 8721; -.
DR   DisGeNET; 8721; -.
DR   GeneCards; EDF1; -.
DR   HGNC; HGNC:3164; EDF1.
DR   HPA; ENSG00000107223; Low tissue specificity.
DR   MIM; 605107; gene.
DR   neXtProt; NX_O60869; -.
DR   OpenTargets; ENSG00000107223; -.
DR   PharmGKB; PA27604; -.
DR   VEuPathDB; HostDB:ENSG00000107223; -.
DR   eggNOG; KOG3398; Eukaryota.
DR   GeneTree; ENSGT00390000008519; -.
DR   HOGENOM; CLU_112609_0_1_1; -.
DR   InParanoid; O60869; -.
DR   OMA; GKNKSCK; -.
DR   OrthoDB; 10253401at2759; -.
DR   PAN-GO; O60869; 1 GO annotation based on evolutionary models.
DR   PhylomeDB; O60869; -.
DR   TreeFam; TF300064; -.
DR   PathwayCommons; O60869; -.
DR   SignaLink; O60869; -.
DR   SIGNOR; O60869; -.
DR   BioGRID-ORCS; 8721; 89 hits in 1183 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   ChiTaRS; EDF1; human.
DR   EvolutionaryTrace; O60869; -.
DR   GeneWiki; EDF1; -.
DR   GenomeRNAi; 8721; -.
DR   Pharos; O60869; Tbio.
DR   PRO; PR:O60869; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O60869; protein.
DR   Bgee; ENSG00000107223; Expressed in parotid gland and 204 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0001094; F:TFIID-class transcription factor complex binding; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; IMP:UniProtKB.
DR   GO; GO:0045446; P:endothelial cell differentiation; TAS:UniProtKB.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; TAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; TAS:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; TAS:UniProtKB.
DR   CDD; cd00093; HTH_XRE; 1.
DR   FunFam; 1.10.260.40:FF:000015; Endothelial differentiation-related factor 1; 1.
DR   Gene3D; 1.10.260.40; lambda repressor-like DNA-binding domains; 1.
DR   InterPro; IPR001387; Cro/C1-type_HTH.
DR   InterPro; IPR010982; Lambda_DNA-bd_dom_sf.
DR   InterPro; IPR013729; MBF1_N.
DR   PANTHER; PTHR10245:SF15; ENDOTHELIAL DIFFERENTIATION-RELATED FACTOR 1; 1.
DR   PANTHER; PTHR10245; ENDOTHELIAL DIFFERENTIATION-RELATED FACTOR 1 MULTIPROTEIN BRIDGING FACTOR 1; 1.
DR   Pfam; PF01381; HTH_3; 1.
DR   Pfam; PF08523; MBF1; 1.
DR   SMART; SM00530; HTH_XRE; 1.
DR   SUPFAM; SSF47413; lambda repressor-like DNA-binding domains; 1.
DR   PROSITE; PS50943; HTH_CROC1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Calmodulin-binding; Cytoplasm; Developmental protein; Differentiation;
KW   Direct protein sequencing; DNA-binding; Methylation; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome;
KW   Transcription; Transcription regulation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.7, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:25944712"
FT   CHAIN           2..148
FT                   /note="Endothelial differentiation-related factor 1"
FT                   /id="PRO_0000149795"
FT   DOMAIN          81..135
FT                   /note="HTH cro/C1-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00257"
FT   DNA_BIND        92..111
FT                   /note="H-T-H motif"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00257"
FT   REGION          33..66
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          37..113
FT                   /note="Interaction with NR5A2, PPARG and NR1H3"
FT                   /evidence="ECO:0000269|PubMed:12040021"
FT   REGION          69..108
FT                   /note="Interaction with TBP and NR5A1"
FT                   /evidence="ECO:0000269|PubMed:10567391"
FT   MOTIF           81..88
FT                   /note="IQ motif"
FT   COMPBIAS        33..42
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        48..58
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.7, ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22223895, ECO:0007744|PubMed:25944712"
FT   MOD_RES         4
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         25
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0007744|PubMed:24129315"
FT   VAR_SEQ         129..148
FT                   /note="GLKLRGKDIGKPIEKGPRAK -> DVGTRSARVLRAQ (in isoform
FT                   3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_054701"
FT   VAR_SEQ         130..148
FT                   /note="LKLRGKDIGKPIEKGPRAK -> ECPSTLRRVR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10567391"
FT                   /id="VSP_013336"
FT   MUTAGEN         40
FT                   /note="T->D: Loss of interaction with CALM; when associated
FT                   with D-58; D-91 and D-111."
FT                   /evidence="ECO:0000269|PubMed:10816571"
FT   MUTAGEN         58
FT                   /note="T->D: Loss of interaction with CALM; when associated
FT                   with D-40; D-91 and D-111."
FT                   /evidence="ECO:0000269|PubMed:10816571"
FT   MUTAGEN         65
FT                   /note="T->D: No effect on CALM-binding. No effect; when
FT                   associated with D-74."
FT                   /evidence="ECO:0000269|PubMed:15112053"
FT   MUTAGEN         74
FT                   /note="T->D: No effect on CALM-binding. No effect; when
FT                   associated with D-65."
FT                   /evidence="ECO:0000269|PubMed:15112053"
FT   MUTAGEN         87
FT                   /note="S->A: No effect on CALM-binding."
FT                   /evidence="ECO:0000269|PubMed:15112053"
FT   MUTAGEN         87
FT                   /note="S->D: Loss of interaction with CALM and higher
FT                   affinity for TBP. Same effect; when associated with D-65
FT                   and D-74."
FT                   /evidence="ECO:0000269|PubMed:15112053"
FT   MUTAGEN         91
FT                   /note="T->A: No effect on CALM-binding."
FT                   /evidence="ECO:0000269|PubMed:10816571"
FT   MUTAGEN         91
FT                   /note="T->D: Partial loss of interaction with CALM.
FT                   Complete loss of interaction; when associated with D-40;
FT                   D-58 and D-111."
FT                   /evidence="ECO:0000269|PubMed:10816571"
FT   MUTAGEN         111
FT                   /note="S->D: Loss of interaction with CALM; when associated
FT                   with D-40; D-58 and D-91."
FT                   /evidence="ECO:0000269|PubMed:10816571"
FT   HELIX           25..32
FT                   /evidence="ECO:0007829|PDB:6ZVH"
FT   HELIX           58..63
FT                   /evidence="ECO:0007829|PDB:6ZVH"
FT   HELIX           75..86
FT                   /evidence="ECO:0007829|PDB:6ZVH"
FT   TURN            87..89
FT                   /evidence="ECO:0007829|PDB:6ZVH"
FT   HELIX           92..98
FT                   /evidence="ECO:0007829|PDB:6ZVH"
FT   HELIX           103..110
FT                   /evidence="ECO:0007829|PDB:6ZVH"
FT   HELIX           118..128
FT                   /evidence="ECO:0007829|PDB:6ZVH"
FT   TURN            135..138
FT                   /evidence="ECO:0007829|PDB:1X57"
FT   STRAND          140..143
FT                   /evidence="ECO:0007829|PDB:1X57"
SQ   SEQUENCE   148 AA;  16369 MW;  ADC2C5384BF85C11 CRC64;
     MAESDWDTVT VLRKKGPTAA QAKSKQAILA AQRRGEDVET SKKWAAGQNK QHSITKNTAK
     LDRETEELHH DRVTLEVGKV IQQGRQSKGL TQKDLATKIN EKPQVIADYE SGRAIPNNQV
     LGKIERAIGL KLRGKDIGKP IEKGPRAK
//
